Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization - Wikidata - wikimedia - TriplyDB

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization

http://www.wikidata.org/entity/Q37199687

about

Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events Transient dynamics of Aβ contribute to toxicity in Alzheimer's disease Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease Neuropathological alterations in Alzheimer disease A window into the heterogeneity of human cerebrospinal fluid Aβ peptides Cerebrospinal fluid and blood biomarkers in Alzheimer's disease Spines, plasticity, and cognition in Alzheimer's model mice FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis Amyloid beta from axons and dendrites reduces local spine number and plasticity.Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation.Brain amyloid-β oligomers in ageing and Alzheimer's disease.Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life.Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains Computational identification of potential multitarget treatments for ameliorating the adverse effects of amyloid-β on synaptic plasticity Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease.Quantifying prefibrillar amyloids in vitro by using a "thioflavin-like" spectroscopic method.Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia.Tissue transglutaminase-mediated glutamine deamidation of beta-amyloid peptide increases peptide solubility, whereas enzymatic cross-linking and peptide fragmentation may serve as molecular triggers for rapid peptide aggregation Targeting Abeta and tau in Alzheimer's disease, an early interim report Anti-amyloidogenic activity of IgGs contained in normal plasma Amyloid-beta immunotherapy for Alzheimer's disease Association of the RAGE G82S polymorphism with Alzheimer's disease.Development and validation of a yeast high-throughput screen for inhibitors of Aβ₄₂ oligomerization.Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines.Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes.Cognition, glucose metabolism and amyloid burden in Alzheimer's disease.Selective induction of calcineurin activity and signaling by oligomeric amyloid beta Abeta(1-42) enhances neuronal excitability in the CA1 via NR2B subunit-containing NMDA receptors Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats.Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils.

P2860

Q24298670-9D0AEBE8-999E-4352-A28D-DF5009136BE4 Q24329069-0EBCE376-155B-4DD2-A106-1D3AC12C2FEB Q24645499-A6C31000-7E67-4502-AA96-52792081ACA3 Q26781635-71DE3D0A-157A-431F-A0E3-FF50C52D82D9 Q26827421-3573860F-6CFF-4FA9-B0D4-C165936FC011 Q26853610-F4FC8273-2436-4B67-A8C5-9129FF4A012B Q27003314-E27A321E-E62C-49D0-9A8F-DFEF640E0AF3 Q27010785-CB0BDEB9-F257-4CCF-A947-7BA242DE8E89 Q27023758-8E253D0C-6BAD-491B-876D-CF34E5653149 Q27691328-DD092272-2D98-49FE-A984-283A855A4E7F Q28534810-C7901E19-E8C7-4C10-A98D-7870C0344435 Q28743838-54416655-5E71-4DA2-A603-10CA81A4D4CF Q30486176-2207086A-8493-4893-B8CE-38334340C2BE Q30491245-05EC7B96-97BB-4F84-A238-32B075BD3D5D Q30497751-8A1C303D-8855-4EA3-BA2B-EBDF0B0F2C1D Q30511922-0235E0C6-6473-4B56-9C19-8090398541E9 Q30535426-21EB1685-FDBE-4FF0-B151-3C9697F23C43 Q30539133-F353AB79-0656-42CF-87FB-B7AC3018D7DC Q31159582-BA6703A2-DD82-41C8-A459-80541DC680DB Q33292558-10CFB7DB-2E0A-4EF7-8E56-0D5DDBE98C18 Q33569608-03DC32FB-778E-47B5-A3FD-C60E140B1568 Q33611723-DEA5F271-5317-47BB-8F5E-95F65CD03B73 Q33638748-7ACCB19E-CE71-4F6F-AFF0-C43285FCA8DC Q33647141-31E13CE4-FD14-4CC8-A9AC-051A92AA89CD Q33718694-0A770F43-B1A5-47CB-A3ED-4B85870B354D Q33759956-E22CB811-D86F-45D6-B00F-415AECA12FCF Q33808415-1E0515A4-B33E-4EBB-BD2D-C2E5D733141B Q33814180-2514AB86-6698-4289-906E-D747345BBBC4 Q33829008-4227DAC5-F389-4A39-983C-E0A7ED28F227 Q33903503-89B5C067-6B16-4D97-BA4F-5C3DF04A64DA Q33954737-4A51BBCD-3C4F-4D41-835C-F87BF60F5CC4 Q33956505-E2B3E9A2-9740-40F6-BB68-5CF233027ACF Q33979228-C6B313A2-BFE9-403F-B21E-1B54EE7F4475 Q33993315-2620EDC4-73DB-4ADF-901A-4F30457197F3 Q34031193-A117E10A-A019-4DD7-8286-F62EE55E7694 Q34061233-F89732A5-55BB-48A2-87F7-F38164EFE2B2 Q34194579-F62E79AA-BCD6-4F87-B868-5C5C3149C885 Q34208684-463CE004-C906-4447-A654-AE8795A50DB2 Q34211231-32BBA21D-02BD-4B2B-B1F7-F858706045E3 Q34330681-A5D4E80E-F047-4AE0-A8A3-40E640659864

P2860

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization

http://www.wikidata.org/entity/Q37199687

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Amyloid beta protein dimer-con ...... systemic passive immunization

@en

Amyloid beta protein dimer-con ...... systemic passive immunization.

@nl

type

label

Amyloid beta protein dimer-con ...... systemic passive immunization

@en

Amyloid beta protein dimer-con ...... systemic passive immunization.

@nl

prefLabel

Amyloid beta protein dimer-con ...... systemic passive immunization

@en

Amyloid beta protein dimer-con ...... systemic passive immunization.

@nl

P1433

Q37199687-F699B6AA-F432-4AA8-A968-34720EEC1362

P1476

Q37199687-11AFA281-F97E-481D-A965-1B30B9C1F4E8

P2093

Q37199687-094F4994-9B44-4C04-9F97-67430F30DB7E

Q37199687-45456315-9905-48F1-87B3-F2B1995938B9

Q37199687-57DF2C4C-7979-4EEC-8667-D413B90696E1

Q37199687-938C110E-A091-4447-908E-975D637DB739

Q37199687-95FFAE35-457C-4F73-A0AF-754AE1B21775

Q37199687-ADF3388E-42B3-4A11-B0C2-80186C3DFFFC

Q37199687-BFE968C5-23AE-4A88-B312-FA871B0409EA

Q37199687-CD80DC14-81B7-4E9E-A007-2BCD1782ACF4

Q37199687-E3C6F856-4195-4A28-88D6-18A4A75ADC0E

Q37199687-F5E64333-3C04-412F-9A97-7179C42117D7

P2860

Q37199687-0FE42C27-B53C-4BCE-AAFB-2D675EFD69AE

Q37199687-224C149E-B6D9-477A-A16A-6A140DFE0C69

Q37199687-2582D0C1-AE47-42E0-87F4-C5C998D13D1B

Q37199687-27C66ADD-C8C8-4CA0-A1A8-463273C4C19A

Q37199687-290AC9E0-CF5C-4DCC-B956-F1E1FCEA8916

Q37199687-36E234DC-71C4-47BE-A7F1-C01367C18B60

Q37199687-3A60089A-F652-4B16-8CC5-78FA022A3DF4

Q37199687-40BBADF5-6DB8-40EF-B8CA-EAC825842963

Q37199687-428C1AF9-C64D-4D3E-9936-88E4EF3E6DE4

Q37199687-5860767E-E7F6-45D2-B8FC-268638257A60

P304

Q37199687-B7096662-3E69-4BB9-B93E-65663C4C004D

P31

Q37199687-6D4729C0-5CD9-44C9-B2D9-AB21E59F6432

P356

Q37199687-36C62C54-47BF-4B82-8FED-C4213FC80B75

P407

Q37199687-93E3454A-BB94-4FBB-BF6F-CCA5C693F732

P433

Q37199687-6AD875B3-BD55-41C8-A68F-F72090367070

P478

Q37199687-A5588CE0-9BA3-4891-9A9F-8334C3DD2A18

P50

Q37199687-40410AC5-3C79-422E-A676-D72C8F585919

Q37199687-4D932F8B-2AB5-472B-B101-C7955FCD1DE9

Q37199687-96B117C1-4A37-4C6D-9FA8-AC01B5FF827B

Q37199687-E59F74E6-2AF0-4EFC-8C8A-7E93B9B697D7

P577

Q37199687-68301999-64CA-4187-9927-739EC879BF26

P698

Q37199687-878DA658-87E6-49A0-B88E-7B6CBDF17752

P921

Q37199687-967F8493-8AE9-4094-8849-55289DE08A84

P932

Q37199687-EDA7037D-72F5-4C1D-ACDB-3DC0D2AA5097

P356

JNEUROSCI.5161-07.2008

P1433

Journal of Neuroscience

P1476

Amyloid beta protein dimer-con ...... systemic passive immunization

@en

P2093

Alfred T Welzel

http://www.w3.org/2001/XMLSchema#string

Anders Wallin

http://www.w3.org/2001/XMLSchema#string

Cynthia A Lemere

http://www.w3.org/2001/XMLSchema#string

Dennis J Selkoe

http://www.w3.org/2001/XMLSchema#string

Dominic M Walsh

http://www.w3.org/2001/XMLSchema#string

Igor Klyubin

http://www.w3.org/2001/XMLSchema#string

Roger Anwyl

http://www.w3.org/2001/XMLSchema#string

Vicki Betts

http://www.w3.org/2001/XMLSchema#string

William K Cullen

http://www.w3.org/2001/XMLSchema#string

Ying Peng

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

Evidence that production and release of amyloid beta-protein involves the endocytic pathway

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

A specific amyloid-beta protein assembly in the brain impairs memory

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

P304

4231-4237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.5161-07.2008

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Wisniewski

Henrik Zetterberg

Michael J Rowan

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18417702

http://www.w3.org/2001/XMLSchema#string

P921

P932

2685151

http://www.w3.org/2001/XMLSchema#string